

Christopher Seaman

e chris@badmath.org
w <https://badmath.org>
t +1 (212) 365 - 8940

Experience

Health Data Science Lead | **UCSF**

2023 - now

- Developed and delivered a new course on diverse data science applications using Python within UCSF's Health Data Science Masters Program
- Instructed students on various essential topics, including SQL, data cleaning, model creation & evaluation, computer vision, and creating an LLM from scratch
- Led end-to-end data science projects on multi-site biomedical research covering: data architecture, pipelines, governance, analysis, and ML implementations/assessment.

Head of Data Science (fractional) | **Bay View Analytics**

2023 - now

- Led bio- and health-tech consulting in digital health, diagnostics, therapeutics, and education sectors
- Provided strategic analytical guidance, resulting in successful FDA approvals and iterative ML solutions for enhanced efficacy and improved product/market-fit

Director - Experimentation | **1Password**

2022 - 2022

- Founded and led the Experimentation and Marketing Analytics department
- Spearheaded the creation of an A/B testing platform, including development of a high-performing data science team and achieving multiple 20%+ wins
- Held responsibility for top-of-funnel reporting, budget/forecasting, and governance

Director - Data Science & Growth | **Rollbar**

2020 - 2021

- Led initiatives to establish company-wide growth and data science strategies & roadmaps
- Established effective experimentation methodology, process, and prioritization
- Led ML initiatives, achieving 35% error grouping improvement and an 80% reduction in false alerts, addressing customer concerns and reducing support tickets

Founder | **Monett**

2019 - 2019

- Co-founded a startup enhancing financial services for independent contractors
- Led product and research efforts, recruited engineering & design talent, and guided sprint and epic priorities during MVP development

Growth & Monetization Lead | **Dropbox**

2017 - 2018

- Led 10 PMs, boosting individual plan paid conversion by \$80m+ ARR
- Launched mobile free trials and revamped over-quota flow (major revenue driver), both \$20m+ wins

Data Science Lead | **Atlassian**

2013 - 2017

- Designed and implemented the data platform for the marketing stack, ensuring data reliability, performance, and security
- Built A/B testing platform, marketing attribution, and causal inference achieving 250,000+ MAU and significant cost savings in marketing
- Grew team from one data scientist (me) to maturity (5 directs), as well as recruiting data engineering (4) and marketing analytics (10) dedicated functions

Education

M.A. in Mathematics (Ph.D. all but dissertation) | **City University of New York**
Bachelor of Arts in mathematics, cum laude | **Wheaton College**

2010
2002

Nonprofit

Board of Directors, Governance Chair | **Felton Institute**

2018 - 2021

Publications

Ackley SF, Andrews RM, **Seaman C**, Flanders M, Chen R, Wang J, Lopes G, Sims KD, Buto P, Ferguson E, Allen IE, Glymour MM. Trends in the Distribution of P Values in Epidemiology Journals: A Statistical, P-Curve, and Simulation Study. *American Journal of Epidemiology*. 2025; *Advance Article*

Seaman C, Allen IE, Seaman JE. Statistics Spotlight: One Hot Dummy. *Quality Progress*. 2024 July; 57(7):48-51.

Seaman C, Allen IE, Seaman JE. Statistics Spotlight: Dissecting Discrimination. *Quality Progress*. 2020 August; 53 (8): 47-49.

Seaman C, Allen IE, Seaman JE. Statistics Spotlight: The Complete Picture. *Quality Progress*. 2019 February; 52 (2): 52-56.

Seaman JE, **Seaman C**, Allen IE. Statistics Spotlight: So Many Variables, So Few Observations. *Quality Progress*. 2013 September; 46 (9):34.

Reynolds M, Stephen R, **Seaman C**, Rajagopalan K. Persistence and Adherence to Disease Modifying Drugs Among Patients with Multiple Sclerosis, *Current Medical Research & Opinion*, 2010 March; 26 (3): 663-674.

Reynolds M, Stephen R, **Seaman C**, Rajagopalan K. Healthcare Resource Utilization Following Switch or Discontinuation in Multiple Sclerosis Patients on Disease Modifying Drugs, *Journal of Medical Economics*, 2010 March; 13 (1): 90-98.

Seaman C, Boklan KD, Dent AW. Broadcast Encryption with Multiple Trust Centers and Dynamic Coalitions, featured presentation at LatinCRYPT 2010, also presented at Annual Conference of the International Technology Alliance 2009.

Leff HS, Chow CM, Pepin R, Conley J, Allen IE, **Seaman C**. Does One Size Fit All? What We Can & Can't Learn from Meta-Analysis of Housing Models for Persons with Mental Illness, *Psychiatric Services*, 2009 April; 60 (4): 473-82.

Allen IE, **Seaman C**. Statistics Spotlight: Predicting Success, *Quality Progress*, 2009 February; 42 (2): 60-63.

Nordstrom BL, **Seaman C**, Reynolds MW, Rajagopalan K. Medical Costs Associated with Treatment Change in Multiple Sclerosis, presented at International Society For Pharmacoeconomics and Outcomes Research 13th Annual International Meeting, 2008 November.

Allen IE, **Seaman C**. Statistics Spotlight: The Trusty Jackknife, *Quality Progress*, 2008 July; 41 (7): 56-58.

Allen IE, **Seaman C**. Statistics Spotlight: Match Game, *Quality Progress*, 2008 February; 41(2): 56-58.

Allen IE, **Seaman C**, Statistics Spotlight: Data Mining in Quality and Reliability, chapter in *Encyclopedia of Statistics in Quality and Reliability*, edited by Fabrizio Ruggeri, Frederick Faltin, and Ron Kenett, John Wiley & Sons Ltd, 2008.

Reynolds M, **Seaman C**, Rajagopalan K, Roth E. Real-World Assessment of Patient Adherence and Treatment Discontinuation Among Different Treatments for Multiple Sclerosis, presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2007 October.

Allen IE, **Seaman C**. Statistics Spotlight: Likert Scales and Data Analyses, *Quality Progress*, 2007 July; 40 (7): 64-65.

Ross SD, Allen IE, Henry DH, **Seaman C**, Sercus B, Goodnough LT. Clinical Benefits and Risks Associated with Epoetin and Darbepoetin in Patients with Chemotherapy-Induced Anemia: A Systematic Review of the Literature, *Journal for Supportive Oncology*, 2007 April; 5 (4,supplement 2): 20-21.

Allen IE, **Seaman C**. Statistics Spotlight: Superiority, Equivalence and Non-Inferiority, *Quality Progress*, 2007 February; 40 (2).

Haas T (listed within article as Allen IE, **Seaman C**). Top Schools: 2006, *Philadelphia Magazine*, 2006 September.

Ross SD, Allen IE, Henry DH, **Seaman C**, Sercus B, Goodnough LT. Clinical Benefits and Risks Associated with Epoetin and Darbepoetin in Patients with Chemotherapy-Induced Anemia: A Systematic Review of the Literature, *Clinical Therapeutics*, 2006 June; 28(6): 801-31, presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer, 2006 June.

Allen IE, **Seaman C**. Statistics Spotlight: Different, Equivalent or Both?, *Quality Progress*, 2006 July; 39 (7).

Olkin I, Allen IE, **Seaman C**. Hierarchical Modeling Using Individual Patient Meta-Analysis, presented at the New England Statistical Symposium, 2006 April.

Taylor T, et al (including **Seaman C**). Human chromosome 11 DNA Sequence and Analysis Including Novel Gene Identification, *Nature*, 2006 March 23, 440 (7083): 497-500.

Allen IE, **Seaman C**. Statistics Spotlight: Data Mining for Quality, *Quality Progress*, 2006 February; 39 (2).

Ozment K (in article as Allen IE, **Seaman C**). Smart Answers (the Best Schools), *Boston Magazine*, 2005 September.

Allen IE, **Seaman C**. Statistics Spotlight: Cumulative Meta-Analysis, *Quality Progress*, 2005 April; 38 (4), also *Babson Free Press*, 2005 May.

International Human Genome Sequencing Consortium (full author list in supplemental material). Finishing the Euchromatic Sequence of the Human Genome, *Nature*, 2004 October 21; 431(7011): 931-45.